行情

TGTX

TGTX

TG Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

5.59
+0.23
+4.29%
盘后: 5.59 0 0.00% 16:29 10/17 EDT
开盘
5.39
昨收
5.36
最高
5.62
最低
5.33
成交量
95.07万
成交额
--
52周最高
9.38
52周最低
3.320
市值
5.30亿
市盈率(TTM)
-2.8703
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TGTX 新闻

  • 沙特阿美:IPO时机将取决于市场条件和股东
  • 新浪财经.2小时前
  • 如何投资红利ETF:耐心比择时更重要么?
  • 新浪财经.2小时前
  • 易纲会见美联储主席鲍威尔 交换了对货币政策等看法
  • 央行.2小时前
  • 日本预计美日贸易协定将使日本GDP增加0.8%
  • 新浪财经.3小时前

更多

所属板块

生物技术和医学研究
+0.95%
制药与医学研究
+0.61%

热门股票

名称
价格
涨跌幅

TGTX 简况

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
展开

Webull提供TG Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。